CoChat

TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis

Open access
Wang, Xiaobo, Zeldin, Sharon, Shi, Hongxue, Zhu, Changyu, Saito, Yoshinobu, Corey, Kathleen E., Osganian, Stephanie A., Remotti, Helen E., Verna, Elizabeth C., Pajvani, Utpal B., Schwabe, Robert F., Tabas, Ira · 2022 · Journal of Hepatology
Cited by 42

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS: Non-alcoholic steatohepatitis (NASH) is a leading cause of hepatocellular carcinoma (HCC), but mechanisms linking NASH to eventual tumor formation remain poorly understood. Herein, we investigate the role of TAZ/WWTR1, which is induced in hepatocytes in NASH, in the progression of NASH to HCC. METHODS: The roles of hepatocyte TAZ and its downstream targets were investigated in diet-induced and genetic models of NASH-HCC using gene-targeting, adeno-associated virus 8 (AAV8)-H1-mediated gene silencing, or AAV8-TBG-mediated gene expression. The biochemical signature of the newly elucidated pathway was probed in liver specimens from humans with NASH-HCC. RESULTS: When hepatocyte-TAZ was silenced in mice with pre-tumor NASH using AAV8-H1-shTaz (short-hairpin Taz), subsequent HCC tumor development was suppressed. In this setting, the tumor-suppressing effect of shTaz was not dependent of TAZ silencing in the tumors themselves and could be dissociated from the NASH-suppressing effects of shTaz. The mechanism linking pre-tumor hepatocyte-TAZ to eventual tumor formation involved TAZ-mediated induction of the NOX2-encoding gene Cybb, which led to NADPH-mediated oxidative DNA damage. As evidence, DNA damage and tumor formation could be suppressed by treatment of pre-tumor NASH mice with AAV8-H1-shCybb; AAV8-TBG-OGG1, encoding the oxidative DNA-repair enzyme 8-oxoguanine glycosylase; or AAV8-TBG-NHEJ1, encoding the dsDNA repair enzyme non-homologous end-joining factor 1. In surrounding non-tumor tissue from human NASH-HCC livers, there were strong correlations between TAZ, NOX2, and oxidative DNA damage. CONCLUSIONS: TAZ in pre-tumor NASH-hepatocytes, via induction of Cybb and NOX2-mediated DNA damage, contributes to subsequent HCC tumor development. These findings illustrate how NASH provides a unique window into the early molecular events that can lead to tumor formation and suggest that NASH therapies targeting TAZ might also prevent NASH-HCC. LAY SUMMARY: Non-alcoholic steatohepatitis (NASH) is emerging as the leading cause of a type of liver cancer called hepatocellular carcinoma (HCC), but molecular events in pre-tumor NASH hepatocytes leading to HCC remain largely unknown. Our study shows that a protein called TAZ in pre-tumor NASH-hepatocytes promotes damage to the DNA of hepatocytes and thereby contributes to eventual HCC. This study reveals a very early event in HCC that is induced in pre-tumor NASH, and the findings suggest that NASH therapies targeting TAZ might also prevent NASH-HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2021.11.031

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Loomba, 2013, The global NAFLD epidemic, Nat Rev Gastroenterol Hepatol, 10, 686, 10.1038/nrgastro.2013.171 · DOI · Paper page
  2. Corey, 2014, Obesity and liver disease: the epidemic of the twenty-first century, Clin Liver Dis, 18, 1, 10.1016/j.cld.2013.09.019 · DOI
  3. Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002/hep.22734 · DOI · Paper page
  4. Linhart, 2015, The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease, Hepatobiliary Surg Nutr, 4, 117
  5. Boege, 2017, A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development, Cancer Cell, 32, 342, 10.1016/j.ccell.2017.08.010 · DOI · Paper page
  6. Kakehashi, 2020, Accumulation of 8-hydroxydeoxyguanosine, L-arginine and glucose metabolites by liver tumor cells are the important characteristic features of metabolic syndrome and non-alcoholic steatohepatitis-associated hepatocarcinogenesis, Int J Mol Sci, 21, 7746, 10.3390/ijms21207746 · DOI
  7. Yang, 2021, Hepatocyte-specific TAZ deletion downregulates p62/Sqstm1 expression in nonalcoholic steatohepatitis, Biochem Biophys Res Commun, 535, 60, 10.1016/j.bbrc.2020.12.038 · DOI
  8. Khajehahmadi, 2019, Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: is TAZ a crucial regulator?, IUBMB Life, 71, 1382, 10.1002/iub.2068 · DOI · Paper page
  9. Pinyol, 2021, Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis, J Hepatol, 75, 865, 10.1016/j.jhep.2021.04.049 · DOI · Paper page
  10. Chuma, 2008, 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection, J Gastroenterol Hepatol, 23, 1431, 10.1111/j.1440-1746.2008.05502.x · DOI
  11. Hagenbeek, 2018, The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors, Sci Signal, 11, 10.1126/scisignal.aaj1757 · DOI · Paper page
  12. Hayashi, 2015, An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression, Cancer Res, 75, 4985, 10.1158/0008-5472.CAN-15-0291 · DOI · Paper page
  13. Wang, 2021, Distinct and overlapping roles of hippo effectors YAP and TAZ during human and mouse hepatocarcinogenesis, Cell Mol Gastroenterol Hepatol, 11, 1095, 10.1016/j.jcmgh.2020.11.008 · DOI
  14. Wang, 2019, A therapeutic silencing RNA targeting hepatocyte TAZ prevents and reverses fibrosis in nonalcoholic steatohepatitis in mice, Hepatol Commun, 3, 1221, 10.1002/hep4.1405 · DOI · Paper page
  15. Zhu, 2021, Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features, J Hepatol, 74, 613, 10.1016/j.jhep.2020.09.032 · DOI
  16. Moon, 2019, High risk of hepatocellular carcinoma development in fibrotic liver: role of the Hippo-YAP/TAZ signaling pathway, Int J Mol Sci, 20, 581, 10.3390/ijms20030581 · DOI
  17. Zhang, 2019, Role of the transcriptional coactivators YAP/TAZ in liver cancer, Curr Opin Cell Biol, 61, 64, 10.1016/j.ceb.2019.07.006 · DOI
  18. Peiseler, 2021, Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma, Cancers (Basel), 13, 10.3390/cancers13040730 · DOI · Paper page
  19. Nishimura, 2001, Mammalian Ogg1/Mmh gene plays a major role in repair of the 8-hydroxyguanine lesion in DNA, Prog Nucleic Acid Res Mol Biol, 68, 107, 10.1016/S0079-6603(01)68093-0 · DOI
  20. Okada, 2006, The role of nicotinamide adenine dinucleotide phosphate oxidase-derived reactive oxygen species in the acquisition of metastatic ability of tumor cells, Am J Pathol, 169, 294, 10.2353/ajpath.2006.060073 · DOI
  21. Choi, 2014, Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma, Free Radic Biol Med, 72, 267, 10.1016/j.freeradbiomed.2014.04.020 · DOI

Cited by

See all 42

Metadata

Authors
Wang, X., Zeldin, S., Shi, H., Zhu, C., Saito, Y., Corey, K. E., Osganian, S. A., Remotti, H. E., Verna, E. C., Pajvani, U. B., Schwabe, R. F., & Tabas, I.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2022-04
Volume
76
Issue
4
Pages
910-920
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4200005504
Cited by
42
References
11
FWCI
3.26
Type
journal article
Language
en
Open access
hybrid
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Institutes of Health (DK103818, R01DK116620, DK119767, R01CA190844, R01CA228483)
  • National Cancer Institute (30 CA013696)
  • American Liver Foundation
  • University of Minnesota (HHSN276201200017C)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.